相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy
Michael G. White et al.
BRITISH JOURNAL OF CANCER (2021)
Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing in Non-small Cell Lung Cancer
Fabio Perrotta et al.
CHEST (2020)
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
S. Popat et al.
ANNALS OF ONCOLOGY (2020)
The Value of PD-L1 Expression in metastatic Lymph Nodes of Advanced Non-Small Cell Lung Cancer
Haitang Yang et al.
CHEST (2020)
Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment
Runzhe Chen et al.
CLINICAL CANCER RESEARCH (2020)
Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma
Haitang Yang et al.
CANCERS (2020)
Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications
Yuna Blum et al.
NATURE COMMUNICATIONS (2019)
Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X
Nancy M. Joseph et al.
MODERN PATHOLOGY (2017)
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
Raphael Bueno et al.
NATURE GENETICS (2016)
分享论文
